GLORIA

GEOMAR Library Ocean Research Information Access

X
You have 0 saved results.
Mark results and click the "Add To Watchlist" link in order to add them to this list.

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Seed SRL  (3)
Material
Publisher
  • Seed SRL  (3)
Person/Organisation
Language
Years
  • 1
    Online Resource
    Online Resource
    Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib
    Seed SRL ; 2015
    In:  Clinical Management Issues Vol. 4, No. 5S ( 2015-10-13), p. 9-13
    Details
    In: Clinical Management Issues, Seed SRL, Vol. 4, No. 5S ( 2015-10-13), p. 9-13
    Abstract: We report a case of patient with chronic myeloid leukemia who started imatinib at standard dose and obtained a sub-optimal response at 6 months. Considering the patient as a possible “late responder”, we decided not to change the imatinib dose, but, at 12 months, we did not achieve a complete cytogenetic response. At that time, we decided to switch to a second-generation tyrosine kinase inhibitor (TKI), nilotinib 800 mg/day, obtaining soon a major molecular response. Recently, the retrospective application of European LeukemiaNet guidelines in large cohorts of patients suggested that patients whose response to imatinib is sub-optimal at 6 months showed significantly worse survival. Therefore we can hypothesise that this kind of patients could be eligible for an early switch to second-generation TKI.
    Type of Medium: Online Resource
    ISSN: 2283-3137 , 1973-4832
    URL: Article
    DOI: 10.7175/cmi.v4i5S.1092
    Language: Unknown
    Publisher: Seed SRL
    Publication Date: 2015
    detail.hit.zdb_id: 2744441-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Nilotinib: selective inhibitor as second-line therapy
    Seed SRL ; 2015
    In:  Clinical Management Issues Vol. 4, No. 6S ( 2015-10-13), p. 3-5
    Details
    In: Clinical Management Issues, Seed SRL, Vol. 4, No. 6S ( 2015-10-13), p. 3-5
    Type of Medium: Online Resource
    ISSN: 2283-3137 , 1973-4832
    URL: Article
    DOI: 10.7175/cmi.v4i6S.1096
    Language: Unknown
    Publisher: Seed SRL
    Publication Date: 2015
    detail.hit.zdb_id: 2744441-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
    Seed SRL ; 2015
    In:  Clinical Management Issues Vol. 4, No. 2S ( 2015-10-13), p. 7-11
    Details
    In: Clinical Management Issues, Seed SRL, Vol. 4, No. 2S ( 2015-10-13), p. 7-11
    Abstract: We report a case of a young man affected by Wolf-Parkinson White syndrome, who was diagnosed as having chronic myeloid leukemia. He started imatinib at standard dose of 400 mg/day and he reached a partial cytogenetic response at 6 months, a sub-optimal response according to European LeukemiaNet criteria of 2006. For this reason he increased imatinib dose to 600 mg/day, but after 3 months he suddenly lost his hematologic response. Cytogenetic analysis performed at this time showed a cytogenetic relapse and acquisition of an additional cytogenetic abnormality (trisomy 8). Considering the patient as a failure at this time, he switched to second-generation tyrosine kinase inhibitor, nilotinib at the dose of 800 mg/day. He reached complete cytogenetic remission after 3 months and nilotinib was safely administered without further QTc prolongation.
    Type of Medium: Online Resource
    ISSN: 2283-3137 , 1973-4832
    URL: Article
    DOI: 10.7175/cmi.v4i2S.1070
    Language: Unknown
    Publisher: Seed SRL
    Publication Date: 2015
    detail.hit.zdb_id: 2744441-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...